<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03733496</url>
  </required_header>
  <id_info>
    <org_study_id>PD-1104</org_study_id>
    <nct_id>NCT03733496</nct_id>
  </id_info>
  <brief_title>Observational, Long-term, Extension Study for Participants of Prior VY-AADC01 or VY-AADC02 Studies</brief_title>
  <official_title>An Observational, Long-Term Extension Study for Participants of Prior VY-AADC01 or VY-AADC02 Clinical Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurocrine Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Voyager Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Neurocrine Biosciences</source>
  <brief_summary>
    <textblock>
      An extension study for participants who have completed VY-AADC01 or VY-AADC02 Studies
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 24, 2018</start_date>
  <completion_date type="Anticipated">August 2026</completion_date>
  <primary_completion_date type="Anticipated">August 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)</measure>
    <time_frame>8 years</time_frame>
    <description>Long-term safety of VY-AADC as assessed by Adverse Events and Serious Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in AADC enzyme activity</measure>
    <time_frame>8 years</time_frame>
    <description>Continued expression of AADC as measured by [18F]-fluorodopa (F-Dopa) positron emission tomography (PET)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Participants from VY-AADC01 or VY-AADC02 clinical studies</arm_group_label>
    <description>Participants who have finished participating in Voyager-sponsored VY-AADC01 or VY-AADC02 clinical studies will be invited to participate in this extension study</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants from prior VY-AADC01 or VY-AADC02 clinical studies will be eligible for the
        extension study
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participant in Voyager-sponsored clinical study of VY-AADC01 or VY-AADC02 gene therapy

          2. Ability to comprehend and signed the informed consent, or for participants who are not
             capable of providing consent, have a healthcare proxy, or person with power of
             attorney, who is able and willing to give consent on behalf of the participant

          3. Capable of complying with the protocol

        Exclusion Criteria:

        None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Steve Hersch, MD</last_name>
    <role>Study Director</role>
    <affiliation>Voyager Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>October 19, 2018</study_first_submitted>
  <study_first_submitted_qc>November 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2018</study_first_posted>
  <last_update_submitted>March 25, 2019</last_update_submitted>
  <last_update_submitted_qc>March 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PD</keyword>
  <keyword>Parkinson's Disease</keyword>
  <keyword>Aromatic L-Amino Acid Decarboxylase</keyword>
  <keyword>AADC</keyword>
  <keyword>AAV2</keyword>
  <keyword>AAV2-AADC</keyword>
  <keyword>VY-AADC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

